Idarucizumab
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.
This drug was developed by Boehringer Ingelheim Pharmaceuticals. A study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes. It was FDA approved in October 2015. In the United States the wholesale cost is $3500 US.
